This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, Y. Articles by Weissleder, R. Search for Related Content PubMed PubMed Citation Articles by Tang, Y. Articles by Weissleder, R.

In vivo Assessment of RAS-Dependent Maintenance of Tumor Angiogenesis by Real-time Magnetic Resonance Imaging

¹ Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts; Departments of ² Medical Oncology and ³ Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital; and Departments of ⁴ Dermatology and ⁵ Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Lynda Chin, Dana-Farber Cancer Institute, 44 Binney Street, M413, Boston, MA 02115. Phone: 617-632-6091; E-mail: lynda_chin{at}dfci.harvard.edu or Ralph Weissleder, Center for Molecular Imaging Research, Massachusetts General Hospital, Room 5406, Building 149, 13th Street, Charlestown, MA 02129. Phone: 617-726-8226; Fax: 617-726-5708; E-mail: weissleder{at}helix.mgh.harvard.edu.

New blood vessel formation is a prominent feature of human cancers and tumor progression and is frequently accompanied by the acquisition of an angiogenic phenotype associated with a switch in the balance of proangiogenic and antiangiogenic molecules. This study was designed to investigate the role of activated H-RAS on the angiogenic phenotype of melanoma that arises in the inducible Tyr/Tet-RAS Ink4a/Arf^–/– model using in vivo imaging with histopathologic correlation. We show that loss of RAS activity in fully established melanomas led to a reduction in tumor volume, which was preceded by impairment of vascular function as determined by in vivo magnetic resonance imaging. This correlated with activation of apoptosis in host-derived endothelial cells as well as in tumor cells. Thus, real-time in vivo imaging provided evidence that maintenance of tumor angiogenesis requires activated RAS in this model system, and that loss of vascular integrity upon inactivation of RAS is an active process rather than a consequence of loss of tumor cell viability.

This article has been cited by other articles:

				G. T. Stathopoulos, C. Moschos, H. Loutrari, A. Kollintza, I. Psallidas, S. Karabela, S. Magkouta, Z. Zhou, S. A. Papiris, C. Roussos, et al. Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 50 - 59. [Abstract] [Full Text] [PDF]

				B. B. Ancrile, K. M. O'Hayer, and C. M. Counter Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics Mol. Interv., February 1, 2008; 8(1): 22 - 27. [Abstract] [Full Text] [PDF]

				K. Shchors, E. Shchors, F. Rostker, E. R. Lawlor, L. Brown-Swigart, and G. I. Evan The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta Genes & Dev., September 15, 2006; 20(18): 2527 - 2538. [Abstract] [Full Text] [PDF]

				L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]

				J. FOLKMAN and S. RYEOM Is Oncogene Addiction Angiogenesis-dependent? Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 389 - 397. [Abstract] [PDF]